Hep B screening urged before TNF-alpha inhibitor therapy

July 1, 2012
Hep B screening urged before TNF-alpha inhibitor therapy
All patients with psoriasis should be screened for hepatitis B surface antigen and hepatitis B core antibody prior to the initiation of tumor necrosis factor-alpha inhibitor therapy, according to research published online June 25 in the Journal of the American Academy of Dermatology.

(HealthDay) -- All patients with psoriasis should be screened for hepatitis B surface antigen and hepatitis B core antibody prior to the initiation of tumor necrosis factor-alpha inhibitor therapy, according to research published online June 25 in the Journal of the American Academy of Dermatology.

Amanda Abramson, M.D., from the Baylor University Medical Center in Dallas, and colleagues reviewed the literature for studies to provide guidance for dermatologists on the use of tumor necrosis factor-alpha inhibitory agents (etanercept, adalimumab, and infliximab) for patients with psoriasis who have hepatitis B.

The researchers found that, in patients with psoriasis who are hepatitis B surface antigen-positive, treatment with tumor necrosis factor-alpha inhibitors may result in reactivated hepatitis B. Patients with an isolated positive hepatitis B core antibody may also experience reactivation, although this occurred less frequently. Compared with the other two agents, infliximab was associated with more cases of reactivation and there were fatalities reported with this agent. Evidence suggested that early or pre-emptive antiviral therapy can greatly minimized or eliminate the risk of reactivation.

"Hepatitis B screening is essential prior to the initiation of tumor necrosis factor-alpha inhibitor therapy," the authors write. "Psoriatic patients found to be hepatitis B surface antigen or core antibody-positive should be referred to an appropriate specialist for evaluation and therapy. This would allow for the safe use of tumor necrosis factor-alpha inhibitors in psoriatic patients despite recently published guidelines to the contrary."

Several authors disclosed to the pharmaceutical industry.

Explore further: Hepatitis B screening before chemo deemed cost-effective

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Hepatitis B screening before chemo deemed cost-effective

June 20, 2012
(HealthDay) -- Universal hepatitis B virus (HBV) screening before chemotherapy for lymphoma reduces costs in most settings, according to a study published online June 18 in the Journal of Clinical Oncology.

UVB preferred for treatment of moderate to severe psoriasis

February 24, 2012
(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the ...

Analysis finds mortality from all causes higher among hepatitis C-infected

June 10, 2011
Although liver-related mortality among those infected with hepatitis C is well-documented, little is known about deaths in these patients that are not related to liver problems. A new study published in Clinical Infectious ...

Recommended for you

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

Can previous exposure to west Nile alter the course of Zika?

August 15, 2017
West Nile virus is no stranger to the U.S.-Mexico border; thousands of people in the region have contracted the mosquito-borne virus in the past. But could this previous exposure affect how intensely Zika sickens someone ...

Compounds in desert creosote bush could treat giardia and 'brain-eating' amoeba infections

August 15, 2017
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego and the University of Colorado Anschutz Medical Campus have found that compounds produced by the creosote bush, a ...

New malaria analysis method reveals disease severity in minutes

August 11, 2017
Left untreated, malaria can progress from being mild to severe—and potentially fatal—in 24 hours. So researchers at the University of British Columbia developed a method to quickly and sensitively assess the progression ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.